Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

CRVO

- PMLiVE

Roche loses Indian Tarceva patent battle with Cipla

As Novartis' Glivec patent law challenge begins again

- PMLiVE

Bayer’s Martin Hesse moves to Daiichi Sankyo Europe

Will succeed Max Schöner, who retires in December after 12-years as CFO

Pharma’s use of Pinterest gains momentum

Boehringer, GE Healthcare, Menarini, Novo Nordisk and Bayer have a presence on the social network

Roche - Basel

Roche says pipeline will balance cancer drug patent losses

Has 11 new molecular entities in late-stage portfolio and 11 line extensions

Novartis building

FDA panel backs Novartis’ updated cystic fibrosis drug

New version of inhaled tobramycin therapy is simpler to use

Novartis building

Novartis showcases COPD candidates at ERS meeting

Positive results for three late-stage drugs

Bayer launches late-stage lung condition trial for ciprofloxacin

Study involves the use of Novartis’ T-326 inhaler

Novartis reaffirms commitment to UK respiratory research site

Will slim down and redevelop Horsham facility

- PMLiVE

Novartis eye drug Jetrea effective in phase III

Pharma company and its partner ThromboGenics report positive trial data

- PMLiVE

Pfizer dealt another blow as Torisel fails kidney cancer trial

Results are another setback in company's bid to extend the indications for its mTOR inhibitor

Novartis day

Novartis signs cancer immunotherapy deal with Penn

R&D alliance with the University of Pennsylvania will focus on novel T-cell immunotherapies

- PMLiVE

Interview: Joseph Jimenez, Novartis

Novartis' CEO tells Linda Banks how investing in innovation and parallel development is helping to keep the company at the forefront

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links